HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Burkitt lymphoma is a highly aggressive form of non-Hodgkin lymphoma, a type of cancer that originates in the lymphatic system. Named after British surgeon Denis Burkitt, who first described the disease in African children in the 1950s, Burkitt lymphoma is characterized by its rapid growth and tendency to affect the jaw and facial bones.This type of lymphoma is closely associated with Epstein-Barr virus (EBV) infection, particularly in endemic areas where malaria is prevalent. It primarily occurs in children and young adults but can affect individuals of any age. The disease often presents with swelling, pain, or a mass in the jaw or other facial bones.Burkitt lymphoma is classified into three main types: endemic, sporadic, and immunodeficiency-associated. Endemic Burkitt lymphoma is prevalent in equatorial Africa, where it is linked to malaria and EBV. Sporadic Burkitt lymphoma occurs worldwide and is not geographically restricted. Immunodeficiency-associated Burkitt lymphoma is often seen in individuals with weakened immune systems, such as those with HIV/AIDS.Diagnosis involves a combination of medical history assessment, physical examination, imaging studies, and biopsy. The characteristic features of Burkitt lymphoma cells under the microscope include a "starry sky" appearance due to interspersed macrophages among rapidly dividing lymphoma cells.Treatment typically involves aggressive chemotherapy regimens. Due to its rapid growth, Burkitt lymphoma requires prompt intervention. Rituximab, a monoclonal antibody, is often incorporated into treatment plans. Prognosis varies depending on the type and stage of Burkitt lymphoma, but with timely and intensive therapy, many patients achieve favorable outcomes. Research and clinical trials continue to explore novel therapeutic approaches for Burkitt lymphoma. As our understanding of the disease advances, targeted therapies and immunotherapies may offer new avenues for treatment, offering hope for improved outcomes for individuals affected by this aggressive lymphoma.
